海特生物
(300683)
| 流通市值：27.84亿 | | | 总市值：29.82亿 |
| 流通股本：1.22亿 | | | 总股本：1.31亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 313,759,570.78 | 225,517,028.5 | 159,045,546.74 | 541,449,755.17 |
| 营业收入 | 313,759,570.78 | 225,517,028.5 | 159,045,546.74 | 541,449,755.17 |
| 二、营业总成本 | 443,912,503.96 | 306,332,007.54 | 178,197,247.74 | 673,434,496.86 |
| 营业成本 | 217,908,695.61 | 148,283,925.57 | 97,867,589.99 | 310,569,160.56 |
| 税金及附加 | 5,391,203.09 | 3,614,081.67 | 1,385,598.7 | 8,100,314.69 |
| 销售费用 | 98,819,596.04 | 69,872,539.1 | 34,190,231.92 | 156,138,906.4 |
| 管理费用 | 66,255,531.74 | 46,967,446.01 | 25,876,741.1 | 115,109,494.54 |
| 研发费用 | 58,843,905.58 | 39,372,913.24 | 19,427,504.16 | 88,239,018.34 |
| 财务费用 | -3,306,428.1 | -1,778,898.05 | -550,418.13 | -4,722,397.67 |
| 其中:利息费用 | 714,301.65 | 525,151.83 | 266,563.16 | 1,390,342.84 |
| 其中:利息收入 | 3,972,247.23 | 2,481,555.29 | 920,580.34 | 6,412,947.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,994,632.48 | 1,108,216.31 | 513,127.96 | -12,521,343.58 |
| 加:投资收益 | -2,017,685.45 | -1,865,475.3 | -269,889.68 | 20,643,544.25 |
| 资产处置收益 | -2,365,358.78 | -2,301,165.53 | -2,142,633.52 | -979,179.5 |
| 资产减值损失(新) | -5,904,015.73 | -7,683,474.94 | -8,778,870.56 | -122,704,081.63 |
| 信用减值损失(新) | -2,742,126.42 | 2,918,632.56 | 1,366,639.12 | -1,498,224.87 |
| 其他收益 | 10,521,832.62 | 5,517,562.63 | 2,289,988.06 | 14,939,695.7 |
| 四、营业利润 | -130,665,654.46 | -83,120,683.31 | -26,173,339.62 | -234,104,331.32 |
| 加:营业外收入 | 854,774.49 | 397,996.77 | 235,736.41 | 463,864.56 |
| 减:营业外支出 | 5,324,940.95 | 4,507,885.87 | 895,898.31 | 5,123,045.88 |
| 五、利润总额 | -135,135,820.92 | -87,230,572.41 | -26,833,501.52 | -238,763,512.64 |
| 减:所得税费用 | -13,959,082.33 | -7,342,222.17 | -2,900,341 | -3,333,311.45 |
| 六、净利润 | -121,176,738.59 | -79,888,350.24 | -23,933,160.52 | -235,430,201.19 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -121,176,738.59 | -79,888,350.24 | -23,933,160.52 | -235,430,201.19 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -119,268,116.99 | -78,707,087.58 | -23,046,268.41 | -231,265,718.38 |
| 少数股东损益 | -1,908,621.6 | -1,181,262.66 | -886,892.11 | -4,164,482.81 |
| 扣除非经常损益后的净利润 | -125,713,655.85 | -80,267,132.39 | -23,800,880.94 | -254,686,347.13 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.91 | -0.6 | -0.18 | -1.77 |
| (二)稀释每股收益 | -0.91 | -0.6 | -0.18 | -1.77 |
| 九、综合收益总额 | -121,176,738.59 | -79,888,350.24 | -23,933,160.52 | -235,430,201.19 |
| 归属于母公司股东的综合收益总额 | -119,268,116.99 | -78,707,087.58 | -23,046,268.41 | -231,265,718.38 |
| 归属于少数股东的综合收益总额 | -1,908,621.6 | -1,181,262.66 | -886,892.11 | -4,164,482.81 |
| 公告日期 | 2026-10-23 | 2026-08-24 | 2026-04-24 | 2026-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |